OBJECTIVES:  The aim of this study was to determine the direct medical costs (DMC) of maintenance therapy in brazilian platinum-sensitive ovarian cancer (PSOC) patients based on the Private Healthcare System. METHODS:  The Orizon database, an administrative database containing inpatient and outpatient claims representing 34% of the total Private Health System, was evaluated from Jan/2011 to Dec/2015. Eligibility criteria were patients with ICD-10 code C56 that started treatment among Jan/2012 to Dec/2014, unresectable stages III or IV, treated in first line with any platinum scheme. Platinum sensitive patients were defined as relapse ≥6 months after first platinum-based chemotherapy. DMC of maintenance therapy were calculated as the sum of medical claims for each patient included in the analysis (conversion rate of 1 USD = 3.45 BRL). RESULTS:  Of the 243 patients identified in the database, 62 (25,5%) did maintenance therapy where bevacizumab monotherapy was the most common of all schemes, corresponding to 96,6%. Total maintenance DMC in the subgroup (n = 64) was USD 4,035,872.72 (mean cost = USD 63,060.51/maintenance) and a mean monthly cost of USD 6,917.06. Medicines represented 95,4%, materials 3,1%, exams 0,5%, fees (expenses related to other medical costs) 0,4% and others 0,5% of total costs during the maintenance phase. CONCLUSIONS: The benefit of maintenance therapy in PSOC patients was already demonstrated in clinical trials. Understanding the local current maintenance costs will help payers in decision making specially when novel targeted agents are coming such as olaparib, an oral PARP inhibitor and selective for BRACm patients only, which is already registered and will soon be available in Brazil, not incurring in costs associated with in-clinic infusions.